We serve Chemical Name:2-bromoethylphosphonic acid CAS:999-82-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-bromoethylphosphonic acid
CAS.NO:999-82-6
Synonyms:2-bromoethylphosphonic acid
Molecular Formula:C2H6BrO3P
Molecular Weight:188.94500
HS Code:2931900090
Physical and Chemical Properties:
Melting point:93-95 ºC
Boiling point:N/A
Density:2.012±0.06 g/cm3
Index of Refraction:
PSA:67.34000
Exact Mass:187.92400
LogP:0.55900
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-bromoethylphosphonic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-bromoethylphosphonic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-bromoethylphosphonic acid Use and application,2-bromoethylphosphonic acid technical grade,usp/ep/jp grade.
Related News: There’s a few factors that play into this. 2-bromoethylphosphonic acid manufacturer The workers are demanding that Hong Kong close all border checkpoints to visitors from mainland China, saying they represent a threat to health care workers in the city. 2-bromoethylphosphonic acid supplier INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. 2-bromoethylphosphonic acid vendor A number of UK citizens had trouble reaching the muster point in time for the first flight out because of road blocks and other restrictions in place in Wuhan. 2-bromoethylphosphonic acid factory INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.
